brenipatide

lilly's incretin bet on addiction and mood, not obesity. LY3537031, in two phase 3 trials for alcohol use disorder and depression relapse. no efficacy data published yet.

tier C · weight loss · 11 trials Lilly incretin, no data yet

verdict

a subcutaneous incretin-class peptide from lilly, aimed squarely at relapse prevention: alcohol, opioids, smoking, mood. a serious, well-funded bet with zero published human results so far.

if you're asking whether brenipatide works — nobody can answer that yet on published evidence. the trials began enrolling in october 2025 and run into 2027-2028, and no efficacy results have been posted for any indication. what is real is the scale of the program: eleven registered trials, two of them phase 3. what is not real yet is a number. anyone quoting weight loss or craving data for brenipatide is ahead of the evidence.

if you came for the addiction angle — this is the genuinely novel part. lilly's RENEW program tests brenipatide for relapse prevention across alcohol use disorder (phase 3, n=1100), major depressive disorder (phase 3, n=1000), and phase 2 trials in smoking, opioid use disorder, bipolar disorder, and schizophrenia. the thesis: incretin-class drugs blunt appetite and, in early signals, craving and reward. the RENEW trials ask whether that translates into staying off the substance. it is one of the most interesting open questions in the field, and it is still a question.

if you're asking about sourcing brenipatide — you cannot. this is a brand-new proprietary lilly clinical molecule (code LY3537031). there is no gray-market supply, no disclosed structure, no published dose, and no reconstitution anyone can act on. it exists only inside the trial supply chain. there is nothing here to source or work with.

based on registered clinical trials, not published results. brenipatide is investigational and not available. not medical advice.

why C-tier

brenipatide grades C on the reptides axis, and the reason is availability and evidence, not merit. this is a serious, well-funded, late-stage Lilly program built on a credible mechanism, exactly the kind of molecule that could move up fast. but a C is what the current picture supports: the mechanism is plausible and the developer is top-tier, while the data a researcher can actually evaluate is thin to absent (no published efficacy for any indication) and there is no way to source it. this is not a D, which is reserved for hype outrunning data or failed trials; brenipatide has neither hype nor failure, just a program that has not read out. revisit the grade when the phase 3 data lands.

the core tension

brenipatide is a bet, not a result. lilly is spending phase 3 money to test whether an incretin peptide can keep people off alcohol, opioids, and cigarettes, one of the most interesting ideas in the field. but as of july 2026 there is not a single published efficacy number, and nothing to source. the science is credible and the program is serious; the evidence a researcher can actually evaluate is not here yet.

what it is

A subcutaneous investigational peptide, Lilly development code LY3537031. The INN stem "-patide" marks it as a peptide, and the alcohol-use-disorder trial monitors anti-drug antibodies, consistent with a biologic. Its trial design places it in the incretin family: the phase 1b obesity study washes out prior GLP-1, GIP/GLP-1, GIP/GLP-1/glucagon, and amylin agonists, the standard precaution when the study drug acts on that same axis, and its primary endpoint is body-weight change. Lilly has not publicly disclosed the exact receptor target, so the precise mechanism (GLP-1 alone, a co-agonist, or something adjacent) is not yet on the record.

what it does

The interesting claim is neuropsychiatric, not metabolic. Incretin-class agents suppress appetite and, in animal models and early human signals, appear to dampen craving and reward. Lilly's RENEW program is a broad test of whether that effect can keep people from relapsing, on alcohol, on opioids, on cigarettes, and can delay relapse in mood disorders. As of now these are hypotheses under active test in registered trials, not findings. The metabolic arm (a phase 1b in overweight and obesity) reads like a supporting study rather than the main event.

origin

Built inside Eli Lilly's pipeline, the same house behind tirzepatide and retatrutide, under code LY3537031. The RENEW trials began enrolling in late 2025: the alcohol-use-disorder phase 3 (RENEW-ALC-1) opened in October 2025, the depression phase 3 (RENEW-MDD-1) in early 2026, with phase 2 studies in smoking, opioid use disorder, bipolar disorder, schizophrenia, asthma, and IBS following through 2026. It is an unusually broad first-in-class program for a molecule with no published readouts.

why researchers are interested

It is watched for two reasons. First, the sheer breadth and money: Lilly rarely spends phase 3 dollars across alcohol and depression at once without internal conviction. Second, "incretin peptide for addiction" is one of the most talked-about questions in the space right now, and brenipatide is the most committed test of it. If even one RENEW phase 3 hits, it reframes what this drug class is for. The community tracks it as a story to watch, not a compound to run.

does it work

Unknown, honestly. No efficacy data has been published for any indication. The trials are enrolling, with primary completions spread across 2027 and 2028. The mechanism is plausible and the developer is credible, but plausibility and a big trial budget are not results. Treat any claim of brenipatide efficacy, weight loss or craving reduction, as premature until the readouts land.

claims vs the data

key facts

frequently asked questions

What is brenipatide?

Brenipatide is an investigational subcutaneous peptide developed by Eli Lilly under the code LY3537031. Its trial design places it in the incretin drug family (the class that includes GLP-1 agonists), though Lilly has not publicly disclosed the exact receptor target. Its flagship program, called RENEW, tests it for relapse prevention in addiction and mood disorders. It is in clinical trials as of July 2026 and is not approved or available.

What is brenipatide being studied for?

The headline program is neuropsychiatric: phase 3 trials in alcohol use disorder and major depressive disorder, plus phase 2 trials in smoking, opioid use disorder, bipolar disorder, and schizophrenia. Lilly is also running a phase 1b study in overweight and obesity and phase 2 trials in IBS and asthma. Eleven trials are registered in total, none with published results yet.

How does brenipatide work?

The proposed mechanism is that incretin-class drugs, which act on appetite and reward pathways, may also blunt craving and help prevent relapse. That is the thesis Lilly's RENEW trials are testing. The precise receptor target has not been publicly disclosed, so the exact mechanism is not yet on the record. No efficacy data has been published to confirm the hypothesis.

Can you buy brenipatide?

No. Brenipatide is a proprietary Eli Lilly clinical molecule with no gray-market supply, no disclosed structure, and no published dose. It exists only inside the trial supply chain. There is nothing to source or reconstitute.

Is brenipatide FDA approved?

No. Brenipatide is investigational and in clinical trials. Its two phase 3 trials (alcohol use disorder and depression) began enrolling in late 2025 and early 2026, with primary completions in 2028. Approval, if it ever comes, would depend on the full trial package and a submitted application. No approval date exists.

When will there be brenipatide data?

The earliest registered primary completion is February 2027 (the phase 1b obesity study). The two phase 3 trials complete in 2028. Until then there is no published efficacy data, and any reported results should be treated as premature.

related peptides

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.